A Phase 3 interventional study of Fingolimod 0.5 mg and Fingolimod 1.25 mg in Multiple Sclerosis, sponsored by Novartis. Completed at 105 sites in 22 countries. Open to participants aged 20 Years to 58 Years. Per ClinicalTrials.gov, last updated 2012-07-12.
Sponsored by Novartis · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies testing fingolimod in Multiple Sclerosis — 2 open to participants now, 4 under way, 3 of them phase 3. fingolimod · Multiple Sclerosis.
Among the 34 studies testing fingolimod in Multiple Sclerosis, this one is the 8th largest by enrollment, is one of 3 that started in 2008, is one of 12 in phase 3, and was the 6th registered.
3,271 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.
Browse Multiple Sclerosis studies →2 of the 34 studies testing fingolimod in Multiple Sclerosis are open now, in 3 countries. Recruiting first, the newest first:
TG Therapeutics, Inc. · Sites in United States, Poland, Slovakia
Ages 10–17
Biogen
Ages 10–17
By country, each count listing its studies:
fingolimod: first FDA approval 2010 (GILENYA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 433 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.
This study: 20 Years to 58 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 5 · Phase 3 13 · Phase 4 17
First in 2003; this study’s year is marked. 3 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 920 is above the median of 50 across 2,207 interventional studies indexed under Multiple Sclerosis.
Median enrollment 167 across the 34 interventional studies. Of the 28 that completed or were terminated, 23 (82%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 34 have an industry lead sponsor. The 6 most frequent:
Novartis is the lead sponsor of 714 studies on the registry; none are open to participants now.
106 studies in Multiple Sclerosis by Novartis: 9 open now, 24 under way, 6 of them phase 3. Of 78 finished, 45 (58%) have results posted.
Among the 106 studies in Multiple Sclerosis by Novartis, this one is the 12th largest by enrollment of the 64 interventional ones that give a count, is one of 3 that started in 2008, is one of 23 in phase 3, and was the 6th registered.
Novartis’s Multiple Sclerosis studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 34 studies testing fingolimod in Multiple Sclerosis, from their registry updates:
Among Novartis’s 106 in Multiple Sclerosis:
This tab as a report to print or save as PDF → With an account.
This extension study of was designed to evaluate the long-term safety, tolerability, and efficacy of fingolimod (FTY720) in patients with multiple sclerosis. The Extension study was an extension to the 24-month Core study (CFTY720D2301/NCT00289978).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients continued the same dose to which they had been randomized in the Core study (CFTY720D2301/NCT00289978), fingolimod 1.25 mg/day, in this Extension study.
Drug: Fingolimod 1.25 mg
Patients continued the same dose to which they had been randomized in the Core study, fingolimod 0.5 mg/day, in this Extension study.
Drug: Fingolimod 0.5 mg
Patients randomized to placebo in the Core study were re randomized to fingolimod (either 0.5 or 1.25 mg/day) in this Extension study.
Drug: Fingolimod 0.5 mg · Drug: Fingolimod 1.25 mg
Patients randomized to placebo in the Core study were re randomized to fingolimod 1.25 mg/day in this Extension study.
Drug: Fingolimod 1.25 mg
Patients randomized to placebo in the Core study were re randomized to fingolimod 0.5 mg/day in this Extension study.
Drug: Fingolimod 0.5 mg
Patients self-administered fingolimod 0.5 mg capsules orally once daily.
Also known as: FTY720
Patients self-administered fingolimod 1.25 mg capsules orally once daily.
Also known as: FTY720
Annualized Aggregate Relapse Rate (ARR) During Months 0 to End of Study(Core [CFTY720D2301/NCT00289978] and Extension Study)
ARR is defined as the number of confirmed relapses in a year. A relapse is defined as the appearance of a new or worsening of a previously stable or improving pre-existing neurological abnormality, separated by at least 30 days from onset of a preceding relapse. The abnormality must be present for at least 24 hours and occur in the absence of fever or infection. The annualized ARR for each treatment group was the mean of the annualized ARRs for all patients in the group, calculated as the total number of confirmed relapses divided by the total number of days on study multiplied by 365.25.
Time frame: Months 0 to end of study (maximum up to 60 months)
Time to First Confirmed Relapse up to End of Study: Kaplan-Meier Estimate of Percentage of Patients Relapse-free
A relapse was confirmed when it was accompanied by an increase of at least half a step (0.5) on the Expanded Disability Status Scale (EDSS) or an increase of 1 point on two different Functional Systems (FS) of the EDSS or 2 points on one of the FS (excluding Bowel/Bladder or Cerebral FS). Kaplan-Meier estimates of the percentage of relapse-free patients at end of study and and 95% confidence intervals (CIs) were presented for the treatment groups.
Time frame: Core baseline to end of study (maximum up to 60 months)
Annualized Aggregate Relapse Rate (ARR) During Months 0-24 (Core Study) and Months 24-48 (Extension Study)
ARR is defined as the number of confirmed relapses in a year. A relapse is defined as the appearance of a new or worsening of a previously stable or improving pre-existing neurological abnormality, separated by at least 30 days from onset of a preceding relapse. The abnormality must be present for at least 24 hours and occur in the absence of fever or infection. The annualized ARR for each treatment group was the mean of the annualized ARRs for all patients in the group, calculated as the total number of confirmed relapses divided by the total number of days on study multiplied by 365.25.
Time frame: Months 0-24 (core study) and Months 24-48 (extension study)
Change (Expressed as Ratio) in the Annualized Aggregate Relapse Rate (ARR) From Months 0-24 (Core Study) to Months 24-48 (Extension Study)
ARR is defined as the number of confirmed relapses in a year. A relapse is defined as the appearance of a new or worsening of a previously stable or improving pre-existing neurological abnormality, separated by at least 30 days from onset of a preceding relapse. The abnormality must be present for at least 24 hours and occur in the absence of fever or infection. The annualized ARR for each treatment group was the mean of the annualized ARRs for all patients in the group, calculated as the total number of confirmed relapses divided by the total number of days on study multiplied by 365.25.
Time frame: Months 0-24 (core study) and Months 24-48 (extension study)
Change in Mean Number of New or Newly Enlarged T2 Magnetic Resonance Imaging (MRI) Lesions During Months 0-24 (Core Study) and Months 24-48 (Extension Study)
The number of new or newly enlarged T2 lesions was assessed with T2-weighted MRI scans. A T2-weighted MRI scan utilizes particular values of the echo time (TE) and the repetition time (TR) parameters of image acquisition. Inflammation and tissue damage are seen as bright areas in T2 images and are often referred to as T2 lesions. T2 weighted MRI scans are a sensitive way to evaluate the brain for demyelinating diseases, such as multiple sclerosis.
Time frame: Months 0-24 (core study) and Months 24-48 (extension study)
Percentage of Patients Free of New or Newly Enlarged T2 Magnetic Resonance Imaging (MRI) Lesions During Months 0-24 (Core Study) and Months 24-48 (Extension Study)
The number of new or newly enlarged T2 lesions was assessed with T2-weighted MRI scans. A T2-weighted MRI scan utilizes particular values of the echo time (TE) and the repetition time (TR) parameters of image acquisition. Inflammation and tissue damage are seen as bright areas in T2 images and are often referred to as T2 lesions. T2 weighted MRI scans are a sensitive way to evaluate the brain for demyelinating diseases, such as multiple sclerosis.
Time frame: Months 0-24 (core study) and Months 24-48 (extension study)
Percent Change in Brain Volume From Month 0 to Month 24 (Core Study) and From Month 24 to Month 48 (Extension Study)
Calculations of brain volume change were performed using the structural image evaluation of normalized atrophy (SIENA), software included in the Functional Magnetic Resonance Imaging of the Brain (FMRIB) software library. SIENA is a fully automated method for estimating temporal brain volume change.
Time frame: Months 0-24 (core study) and Months 24-48 (extension study)
Percent Change in Brain Volume From Month 0 End of Study (Core and Extension Study)
Calculations of brain volume change were performed using the structural image evaluation of normalized atrophy (SIENA), software included in the Functional Magnetic Resonance Imaging of the Brain (FMRIB) software library. SIENA is a fully automated method for estimating temporal brain volume change.
Time frame: Months 0 to end of study (maximum up to 60 months)
Time to First 3-month Confirmed Disability Progression up to End of Study Based on Expanded Disability Status Scale (EDSS): Kaplan-Meier Estimate of Percentage of Patients Free of Disability Progression
Kurtzke's Expanded Disability Status Scale (EDSS) is a scale for assessing neurologic impairment in multiple sclerosis (MS) includes a series of scores in each of eight functional systems such as Visual, Brain Stem, Pyramidal, Cerebellar, Sensory, Bowel \& Bladder, Cerebral, and Other. The EDSS steps range from 0 (normal) to 10 (death due to MS). The Kaplan-Meier estimates of the percentage of participants free of disability progression at end of study and their 95% CIs were provided for each treatment group.
Time frame: Core baseline to end of study (maximum up to 60 months)
Of the 1272 patients randomly assigned to treatment in the Core study (ClinicalTrials.gov ID NCT00289978), 1033 completed the 24-month double-blind treatment phase and were eligible to enter the Extension study. A total of 920 of the 1033 patients entered the Extension study and received treatment.
| Milestone | Fingolimod 1.25 mg | Fingolimod 0.5 mg | Placebo | Placebo-fingolimod 1.25 mg | Placebo-fingolimod 0.5 |
|---|---|---|---|---|---|
| Started | 429 | 425 | 418 | 0 | 0 |
| Intent to treat (itt) | 429 | 425 | 418 | 0 | 0 |
| Completed | 332 | 369 | 332 | 0 | 0 |
| Not completed | 97 | 56 | 86 | 0 | 0 |
| Withdrew: Withdrawal by subject | 31 | 17 | 28 | 0 | 0 |
| Withdrew: Adverse event | 22 | 13 | 18 | 0 | 0 |
| Withdrew: Unsatisfactory therapeutic effect | 13 | 6 | 25 | 0 | 0 |
| Withdrew: Abnormal laboratory value(s) | 20 | 9 | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 3 | 5 | 7 | 0 | 0 |
| Withdrew: Protocol violation | 5 | 5 | 4 | 0 | 0 |
| Withdrew: Abnormal test procedure result(s) | 2 | 1 | 1 | 0 | 0 |
| Withdrew: Death | 1 | 0 | 2 | 0 | 0 |
| Milestone | Fingolimod 1.25 mg | Fingolimod 0.5 mg | Placebo | Placebo-fingolimod 1.25 mg | Placebo-fingolimod 0.5 |
|---|---|---|---|---|---|
| Started | 289 | 331 | 0 | 145 | 155 |
| Extension intent to treat population | 287 | 330 | 0 | 145 | 154 |
| From beginning of core at month 24 | 289 | 331 | 0 | 145 | 155 |
| From beginning of core at month 30 | 276 | 324 | 0 | 136 | 152 |
| From beginning of core at month 36 | 270 | 311 | 0 | 130 | 145 |
| From beginning of core at month 42 | 254 | 301 | 0 | 120 | 136 |
| From beginning of core at month 48 | 125 | 152 | 0 | 58 | 67 |
| From beginning of core at month 54 | 31 | 32 | 0 | 11 | 13 |
| Completed | 245 | 290 | 0 | 112 | 126 |
| Not completed | 44 | 41 | 0 | 33 | 29 |
| Withdrew: Abnormal laboratory value(s) | 10 | 5 | 0 | 8 | 3 |
| Withdrew: Abnormal test procedure result(s) | 3 | 1 | 0 | 1 | 3 |
| Withdrew: Administrative problems | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Adverse event | 6 | 9 | 0 | 6 | 10 |
| Withdrew: Lost to follow-up | 2 | 0 | 0 | 1 | 1 |
| Withdrew: Protocol violation | 1 | 1 | 0 | 0 | 0 |
| Withdrew: Subject withdrew consent | 19 | 23 | 0 | 15 | 9 |
| Withdrew: Subject no longer requires study drug | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Unsatisfactory therapeutic effect | 3 | 1 | 0 | 1 | 3 |
ARR is defined as the number of confirmed relapses in a year. A relapse is defined as the appearance of a new or worsening of a previously stable or improving pre-existing neurological abnormality, separated by at least 30 days from onset of a preceding relapse. The abnormality must be present for at least 24 hours and occur in the absence of fever or infection. The annualized ARR for each treatment group was the mean of the annualized ARRs for all patients in the group, calculated as the total number of confirmed relapses divided by the total number of days on study multiplied by 365.25.
| Relapses per year | Fingolimod 1.25 mg | Fingolimod 0.5 mg | Placebo-fingolimod |
|---|---|---|---|
| Annualized Aggregate Relapse Rate (ARR) During Months 0 to End of Study(Core [CFTY720D2301/NCT00289978] and Extension Study) | 0.164 (0.138 to 0.195) | 0.185 (0.158 to 0.217) | 0.357 (0.310 to 0.411) |
The number of new or newly enlarged T2 lesions was assessed with T2-weighted MRI scans. A T2-weighted MRI scan utilizes particular values of the echo time (TE) and the repetition time (TR) parameters of image acquisition. Inflammation and tissue damage are seen as bright areas in T2 images and are often referred to as T2 lesions. T2 weighted MRI scans are a sensitive way to evaluate the brain for demyelinating diseases, such as multiple sclerosis.
| Lesions | Fingolimod 1.25 mg | Fingolimod 0.5 mg | Placebo-fingolimod 1.25 mg | Placebo-fingolimod 0.5 mg |
|---|---|---|---|---|
| Months 0-24 | 2.14 ± 5.234 | 2.66 ± 9.395 | 12.83 ± 17.573 | 8.12 ± 11.083 |
| Months 24-48 | 1.71 ± 4.902 | 2.58 ± 9.256 | 2.34 ± 4.745 | 1.43 ± 2.446 |
| Change from Months 0-24 to Months 24-48 | -0.43 ± 4.393 | -0.09 ± 7.423 | -10.48 ± 15.980 | -6.68 ± 9.876 |
A relapse was confirmed when it was accompanied by an increase of at least half a step (0.5) on the Expanded Disability Status Scale (EDSS) or an increase of 1 point on two different Functional Systems (FS) of the EDSS or 2 points on one of the FS (excluding Bowel/Bladder or Cerebral FS). Kaplan-Meier estimates of the percentage of relapse-free patients at end of study and and 95% confidence intervals (CIs) were presented for the treatment groups.
| Percentage of patients | Fingolimod 1.25 mg | Fingolimod 0.5 mg | Placebo-fingolimod |
|---|---|---|---|
| Time to First Confirmed Relapse up to End of Study: Kaplan-Meier Estimate of Percentage of Patients Relapse-free | 59.85 (53.90 to 65.80) | 59.29 (54.17 to 64.41) | 37.18 (32.15 to 42.22) |
The number of new or newly enlarged T2 lesions was assessed with T2-weighted MRI scans. A T2-weighted MRI scan utilizes particular values of the echo time (TE) and the repetition time (TR) parameters of image acquisition. Inflammation and tissue damage are seen as bright areas in T2 images and are often referred to as T2 lesions. T2 weighted MRI scans are a sensitive way to evaluate the brain for demyelinating diseases, such as multiple sclerosis.
| Percentage of patients | Fingolimod 1.25 mg | Fingolimod 0.5 mg | Placebo-fingolimod 1.25 mg | Placebo-fingolimod 0.5 mg |
|---|---|---|---|---|
| Months 0-24 | 53.2 | 50.3 | 18.5 | 23.2 |
| Months 24-48 | 57.1 | 69.3 | 52.3 | 55.1 |
Calculations of brain volume change were performed using the structural image evaluation of normalized atrophy (SIENA), software included in the Functional Magnetic Resonance Imaging of the Brain (FMRIB) software library. SIENA is a fully automated method for estimating temporal brain volume change.
| Percent change | Fingolimod 1.25 mg | Fingolimod 0.5 mg | Placebo-fingolimod 1.25 mg | Placebo-fingolimod 0.5 mg |
|---|---|---|---|---|
| Month 0 to Month 24, n=75, 109, 41, 49 | -1.011 ± 1.3477 | -0.983 ± 1.6291 | -1.511 ± 1.6401 | -1.419 ± 1.3923 |
| Month 24 to Month 48, n=75, 109, 41, 49 | -0.871 ± 1.4164 | -0.780 ± 1.9266 | -1.103 ± 1.4073 | -0.903 ± 1.1406 |
ARR is defined as the number of confirmed relapses in a year. A relapse is defined as the appearance of a new or worsening of a previously stable or improving pre-existing neurological abnormality, separated by at least 30 days from onset of a preceding relapse. The abnormality must be present for at least 24 hours and occur in the absence of fever or infection. The annualized ARR for each treatment group was the mean of the annualized ARRs for all patients in the group, calculated as the total number of confirmed relapses divided by the total number of days on study multiplied by 365.25.
| Relapses per year | Fingolimod 1.25 mg | Fingolimod 0.5 mg | Placebo-fingolimod 1.25 mg | Placebo-fingolimod 0.5 mg |
|---|---|---|---|---|
| Months 0-24 | 0.064 (0.043 to 0.094) | 0.111 (0.084 to 0.148) | 0.301 (0.230 to 0.393) | 0.292 (0.222 to 0.383) |
| Months 24-48 | 0.074 (0.051 to 0.108) | 0.095 (0.070 to 0.128) | 0.164 (0.117 to 0.231) | 0.130 (0.092 to 0.184) |
ARR is defined as the number of confirmed relapses in a year. A relapse is defined as the appearance of a new or worsening of a previously stable or improving pre-existing neurological abnormality, separated by at least 30 days from onset of a preceding relapse. The abnormality must be present for at least 24 hours and occur in the absence of fever or infection. The annualized ARR for each treatment group was the mean of the annualized ARRs for all patients in the group, calculated as the total number of confirmed relapses divided by the total number of days on study multiplied by 365.25.
| Ratio of relapses per year | Fingolimod 1.25 mg | Fingolimod 0.5 mg | Placebo-fingolimod 1.25 mg | Placebo-fingolimod 0.5 mg |
|---|---|---|---|---|
| Change (Expressed as Ratio) in the Annualized Aggregate Relapse Rate (ARR) From Months 0-24 (Core Study) to Months 24-48 (Extension Study) | 1.164 (0.830 to 1.633) | 0.850 (0.658 to 1.099) | 0.547 (0.390 to 0.767) | 0.446 (0.320 to 0.620) |
Calculations of brain volume change were performed using the structural image evaluation of normalized atrophy (SIENA), software included in the Functional Magnetic Resonance Imaging of the Brain (FMRIB) software library. SIENA is a fully automated method for estimating temporal brain volume change.
| Percent change | Fingolimod 1.25 mg | Fingolimod 0.5 mg | Placebo-fingolimod |
|---|---|---|---|
| Percent Change in Brain Volume From Month 0 End of Study (Core and Extension Study) | -1.639 ± 1.9265 | -1.674 ± 2.1182 | -2.241 ± 2.1873 |
Kurtzke's Expanded Disability Status Scale (EDSS) is a scale for assessing neurologic impairment in multiple sclerosis (MS) includes a series of scores in each of eight functional systems such as Visual, Brain Stem, Pyramidal, Cerebellar, Sensory, Bowel \& Bladder, Cerebral, and Other. The EDSS steps range from 0 (normal) to 10 (death due to MS). The Kaplan-Meier estimates of the percentage of participants free of disability progression at end of study and their 95% CIs were provided for each treatment group.
| Percentage of patients | Fingolimod 1.25 mg | Fingolimod 0.5 mg | Placebo-fingolimod |
|---|---|---|---|
| Time to First 3-month Confirmed Disability Progression up to End of Study Based on Expanded Disability Status Scale (EDSS): Kaplan-Meier Estimate of Percentage of Patients Free of Disability Progression | 74.15 (69.54 to 78.75) | 73.90 (69.44 to 78.37) | 66.28 (61.28 to 71.28) |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Fingolimod 1.25mg | — | 31/289 (10.7%) | 236/289 (81.7%) |
| Fingolimod 0.5mg | — | 31/331 (9.4%) | 273/331 (82.5%) |
| Placebo-Fingolimod 1.25mg | — | 17/145 (11.7%) | 107/145 (73.8%) |
| Placebo-Fingolimod 0.5mg | — | 11/155 (7.1%) | 130/155 (83.9%) |
| Event | Fingolimod 1.25mg | Fingolimod 0.5mg | Placebo-Fingolimod 1.25mg | Placebo-Fingolimod 0.5mg |
|---|---|---|---|---|
| Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/289 | 3/331 | 2/145 | 0/155 |
| DepressionPsychiatric disorders | 0/289 | 0/331 | 2/145 | 0/155 |
| Multiple sclerosis relapseNervous system disorders | 3/289 | 0/331 | 0/145 | 0/155 |
| CholelithiasisHepatobiliary disorders | 2/289 | 0/331 | 0/145 | 0/155 |
| LymphopeniaBlood and lymphatic system disorders | 0/289 | 0/331 | 1/145 | 0/155 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/289 | 0/331 | 1/145 | 0/155 |
| Atrioventricular block second degreeCardiac disorders | 0/289 | 0/331 | 1/145 | 0/155 |
| Atrioventricular extrasystolesCardiac disorders | 0/289 | 0/331 | 1/145 | 0/155 |
| BradycardiaCardiac disorders | 0/289 | 0/331 | 1/145 | 0/155 |
| Irritable bowel syndromeGastrointestinal disorders | 0/289 | 0/331 | 1/145 | 0/155 |
| Event | Fingolimod 1.25mg | Fingolimod 0.5mg | Placebo-Fingolimod 1.25mg | Placebo-Fingolimod 0.5mg |
|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 82/289 | 84/331 | 39/145 | 44/155 |
| LymphopeniaBlood and lymphatic system disorders | 52/289 | 52/331 | 18/145 | 17/155 |
| Upper respiratory tract infectionInfections and infestations | 39/289 | 58/331 | 23/145 | 24/155 |
| HeadacheNervous system disorders | 27/289 | 41/331 | 18/145 | 26/155 |
| Alanine aminotransferase increasedInvestigations | 10/289 | 11/331 | 16/145 | 9/155 |
| InfluenzaInfections and infestations | 30/289 | 33/331 | 9/145 | 12/155 |
| Lymphocyte count decreasedInvestigations | 29/289 | 16/331 | 12/145 | 14/155 |
| HypertensionVascular disorders | 24/289 | 18/331 | 13/145 | 15/155 |
| Back painMusculoskeletal and connective tissue disorders | 20/289 | 21/331 | 12/145 | 14/155 |
| CoughRespiratory, thoracic and mediastinal disorders | 19/289 | 27/331 | 13/145 | 11/155 |
| Age Continuous(years) | Fingolimod 1.25 mg | Fingolimod 0.5 mg | Placebo-fingolimod 1.25 mg | Placebo-fingolimod 0.5 mg | Total |
|---|---|---|---|---|---|
| Mean | 37.2 ± 8.87 | 36.5 ± 8.60 | 36.6 ± 9.21 | 38.1 ± 8.26 | 37.0 ± 8.73 |
| Sex: Female, Male(Participants) | Fingolimod 1.25 mg | Fingolimod 0.5 mg | Placebo-fingolimod 1.25 mg | Placebo-fingolimod 0.5 mg | Total |
|---|---|---|---|---|---|
| Female | 204 | 234 | 107 | 106 | 651 |
| Male | 85 | 97 | 38 | 49 | 269 |
Showing the first 100 of 105 sites across 22 countries. Choose a country and city above to see the rest.
The record gives a start of Feb 2008, a primary completion of Jun 2011 and a completion of Jun 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2012, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fingolimod